How Much Does MEDVi Tirzepatide Cost?

Published on August 23, 2026 | Written by Alec Pow
This article was researched using 15 sources. See our methodology and corrections policy.

MEDVi sells access to a telehealth weight-management program that can connect eligible U.S. patients with a clinician and a pharmacy for compounded GLP-1 medication. Published August 2026 MEDVi tirzepatide figures run from $166 to $199 per month on its public offer, with the conflicting figures documented in an August 2026 pricing review. The checkout amount, refill terms, prescription route, and clinician decision can change what reaches the card statement.

The program charge can cover medication, clinical review, a care plan, support, and shipment rather than a medication-only pharmacy purchase. A patient-specific final amount may remain behind the intake and checkout flow, so the public advertisement should be treated as a starting reference rather than a guaranteed invoice.

MEDVi is billed around a recurring monthly medication program. The per-month amount is tied to the displayed offer, refill language, compounded prescription path, and any move to branded tirzepatide. Renewal timing can also change the near-term bill.

TL;DR: MEDVi publishes a low monthly tirzepatide offer, but conflicting rate text makes the confirmed checkout and renewal amount the figure to budget from.

How Much Does MEDVi Tirzepatide Cost?

• MEDVi’s current page displays $166 (at $30 per hour, earning that amount would take about 5.5 hours of work, before taxes) per month for tirzepatide injection and also states $199 per month in its FAQ and price-lock language, according to the live tirzepatide offer.
• Branded Zepbound self-pay currently starts at $299 per month and reaches $449 per month under qualifying purchase terms, according to LillyDirect Zepbound pricing.
• MEDVi asks for cancellation notice at least 72 hours before the next billing date, according to its cancellation and refund policy.

What you’re actually buying

MEDVi is a telehealth platform rather than the medical practice or dispensing pharmacy itself. Its platform gathers health information, arranges access to affiliated medical professionals, supports payment and scheduling, and coordinates prescription fulfillment when a clinician decides medication is appropriate. MEDVi’s March 2026 user agreement says the medical professionals make independent prescribing decisions and that MEDVi does not act as the pharmacy.

That setup differs from taking a prescription from a local doctor to a retail pharmacy. It also differs from buying FDA-approved Zepbound through a manufacturer-supported cash channel. With MEDVi, the telehealth intake, clinical access, prescription coordination, pharmacy relationship, support, and shipment sit inside one service path. A prescription is not automatic. Clinical eligibility remains separate from payment, and compounded medication is a different product category from FDA-approved branded tirzepatide.

MEDVi beside other weight-loss routes

The low MEDVi public figure looks different once it is placed beside programs that separate membership fees from medication. Some services bundle compounded medication with care, and others charge for medical access before the pharmacy bill appears. Readers comparing MEDVi can use the same monthly unit for each route, then check whether medication is inside or outside that figure.

Route	Published cost reference	Billing structure
Mochi Health	About $278 (about 1.2 full-time workdays at $30 per hour) per month for a tirzepatide cash path in July 2026	Membership plus medication, detailed in the Mochi Health cost analysis
Ro Body	$149 per month continuing membership, with medication separate	Membership and pharmacy costs are separated in the Ro Weight Loss pricing review
Mounjaro retail cash	About $1,000 to $1,200 per month in cited 2024-2025 retail data	Medication-focused pharmacy spending covered in the Mounjaro cash-cost analysis

Branded Zepbound belongs in a separate column from compounded tirzepatide because Lilly controls the FDA-approved product and its manufacturer cash program. Lilly’s December 2025 announcement set vial prices at $299, $399, and $449 per month across eligible dose levels in its Zepbound price reduction.

What MEDVi’s monthly charge covers

MEDVi describes the subscription as a bundled service. Its financial and medical consent language states that medication is included in the MEDVi program and that programs renew automatically unless cancellation is requested before payment is processed, and it also authorizes MEDVi to charge balances tied to orders, goods, or services.

The same consent explains that an OpenLoop Health clinician meets with a patient after checkout and keeps authority over whether a compounded GLP-1 prescription is issued. Those details matter because the monthly card charge is paying for a care-and-fulfillment arrangement, not ownership of a guaranteed prescription before review. The public tirzepatide page also describes physician review, a personalized care plan, guidance, medication shipment, and support as program components.

A shopper should compare the amount displayed at checkout with the recurring rate shown beside it, since the public page currently contains conflicting tirzepatide figures and some template fields in its refill FAQ are not rendered as dollar amounts. MEDVi’s financial consent language also makes the recurring nature of the program explicit.

Checkout still controls the bill. A screenshot of the rate, billing cadence, and renewal language gives the patient a record of the terms presented at purchase.

Three buyer cases

Budget case. A buyer reaches MEDVi through the current promotional page, receives clinical approval, and finds that checkout matches the public headline rate already cited above. The main cost driver is the promotional program rate rather than a separate medical membership charge.

Billing-dispute case. One verified-purchase complaint dated March 16, 2026 describes a promised $199 (about 6.6 hours of work at $30 per hour) per month rate, an initial $279 charge, and a later $399 per month quote. That account appears in ConsumerAffairs customer records. It is one customer’s report, not MEDVi’s published fee schedule, but it shows why retaining checkout records matters.

Branded case. A patient who wants FDA-approved Zepbound instead faces manufacturer cash pricing and refill rules. Under current 2026 purchase terms, qualifying higher-dose fills can be $449 per month. Twelve fills at that amount equal $5,388, using the price and refill conditions in Lilly’s self-pay purchase terms. That is the first arithmetic-based comparison.

Cancellation, hidden billing exposure

The main non-medication billing risk is renewal timing. MEDVi’s stated cutoff means a request received too close to the next billing date can leave the next cycle charged before cancellation takes effect. Monthly subscribers also face restrictive refund language for a month already billed. This turns the cancellation date into a cash-flow issue even when the advertised program has no separate membership or shipping line.

Worked MEDVi total

• Captured monthly figure used for this model, $399.
• Twelve monthly charges, 12 × $399.
• Modeled annual total, $4,788.

This is the second arithmetic-based comparison. It is a model built from a third-party captured rate, not a statement that every MEDVi subscriber will pay that amount. A confirmed MEDVi checkout showing a lower locked rate would produce a lower annual total.

Insurance, dose, and refill timing

MEDVi’s public tirzepatide offer describes its prescriptions as cash-pay, which makes direct insurance reimbursement a different path from the subscription charge. A patient with strong branded-drug coverage may face a very different net bill from a person paying cash for compounded tirzepatide. Commercial coverage can involve deductibles, copays, prior authorization, formulary rules, and manufacturer eligibility, so an insurance card by itself does not establish the final amount.

Dose also works differently across payment models. MEDVi’s promotional language presents a locked monthly rate, yet the conflicting figures on that page leave the exact recurring amount open until checkout. Branded Zepbound has dose-linked cash prices and purchase conditions. A June 2026 GLP-1 pricing survey placed compounded programs in a lower cash band than many branded products and noted that insurance treatment of compounded medication differs from brand coverage. Medical eligibility and dose selection belong with the prescriber, not with a price comparison.

Compounded tirzepatide

Compounded tirzepatide should not be treated as a generic copy of Zepbound or Mounjaro. The manufacturing route, regulatory status, pharmacy preparation, dosing presentation, and FDA review status differ. A July 2026 medically reviewed comparison from Medical News Today states that compounded tirzepatide and Mounjaro are not interchangeable and that compounded products do not go through the same FDA approval review as branded medication.

That distinction explains part of the gap between a low telehealth cash offer and manufacturer pricing. Lower payment alone does not make the products equivalent. Patients also need the name of the dispensing pharmacy, the prescription instructions supplied by the clinician, shipment handling details, and a clear record of what formulation was ordered. Pricing research can show the financial tradeoff, but medication choice, dosing, and suitability require a licensed clinician who has reviewed the patient’s medical information.

Who this cost makes sense for

The MEDVi model fits a narrow buyer profile better than a simple lowest-number comparison suggests. The strongest fit is a cash-paying patient who wants remote clinical access and pharmacy coordination in one recurring program and who is comfortable discussing a compounded prescription with the treating clinician.

Makes sense if

• You plan to pay cash and want medication fulfillment tied to telehealth care.
• You can verify the recurring rate before submitting payment.
• You are comfortable with the clinician deciding whether compounded tirzepatide is medically appropriate.
• You can manage MEDVi’s renewal and cancellation deadlines.

Doesn’t make sense if

• You want only FDA-approved branded Zepbound.
• Your health plan gives you a lower net branded-drug expense.
• You want a local prescriber and retail pharmacy relationship.
• You cannot get a clear recurring rate at checkout.

What we verified

• Checked FDA reporting that compounded GLP-1 products are not FDA approved and that more than 730 adverse-event reports involving compounded tirzepatide had been received by May 31, 2026, on the agency’s GLP-1 safety page.
• Confirmed the April 2026 federal policy clarification on when compounded GLP-1 copies may qualify for statutory exemptions through Reuters regulatory coverage.
• Cross-referenced the end of shortage-based tirzepatide compounding flexibility with the May 2025 STAT legal report.

Answers to Common Questions

How much is MEDVi tirzepatide per month?

MEDVi’s August 2026 public material displays $166 per month in the main tirzepatide offer and $199 per month elsewhere on that same page. Because those figures conflict, buyers should use the recurring checkout amount shown for their enrollment.

Does MEDVi charge a separate membership fee?

The current promotional material presents tirzepatide as a bundled program rather than a medication charge plus a separate membership line. The bundle can include clinical review, care support, prescription coordination, medication, and shipment.

Does insurance cover MEDVi tirzepatide?

MEDVi describes its prescriptions as cash-pay. Insurance treatment of branded tirzepatide is separate and depends on the plan, prescribed indication, formulary, authorization rules, and any manufacturer-program requirements.

Is MEDVi tirzepatide the same as Zepbound?

No. Zepbound is an FDA-approved branded tirzepatide product. Compounded tirzepatide is prepared through a compounding pharmacy and does not receive FDA approval review as a finished drug product.